Revvity logo

RevvityNYSE: RVTY

Profile

Sector:

Healthcare

Country:

United States

IPO:

06 July 1965

Next earnings report:

01 August 2024

Last dividends:

18 April 2024

Next dividends:

19 July 2024
$12.59 B
-50%vs. 3y high
94%vs. sector
-10%vs. 3y high
89%vs. sector
-67%vs. 3y high
51%vs. sector
-29%vs. 3y high
59%vs. sector

Price

after hours | Tue, 02 Jul 2024 21:16:11 GMT
$102.01-$0.99(-0.96%)
$649.92 M$692.54 M
$649.92 M$26.01 M

Analysts recommendations

Institutional Ownership

RVTY Latest News

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
zacks.com03 July 2024 Sentiment: -

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research29 April 2024 Sentiment: POSITIVE

Revity (RVTY) reported a decrease in life sciences segment revenues in the first quarter, but exceeded expectations for both earnings and revenues.

Revvity (RVTY) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research29 April 2024 Sentiment: POSITIVE

While the financial results of Revvity (RVTY) in the quarter ending March 2024 provide an overview of the business performance, it may be beneficial to analyze how certain key metrics stack up against Wall Street projections and figures from the previous year.

Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research29 April 2024 Sentiment: POSITIVE

Revvity (RVTY) reported quarterly earnings of $0.98 per share, surpassing the Zacks Consensus Estimate of $0.94 per share. This is lower than the earnings of $1.01 per share from the previous year.

Revvity beats quarterly estimates on demand for diagnostic equipment
Reuters29 April 2024 Sentiment: POSITIVE

On Monday, Revvity surpassed Wall Street expectations for its quarterly profit and revenue, thanks to stronger-than-anticipated demand for equipment in its diagnostics division.

Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
Zacks Investment Research25 April 2024 Sentiment: POSITIVE

Revvity's (RVTY) newest product is expected to enhance workflow, reduce manual labor, and boost productivity in the lab.

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up
Zacks Investment Research16 April 2024 Sentiment: POSITIVE

Revvity's (RVTY) newest product is expected to greatly speed up drug innovation by streamlining data sharing onto a single platform.

Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
Zacks Investment Research10 April 2024 Sentiment: POSITIVE

Revvity (RVTY) experienced a significant increase in its stock price in the previous session, accompanied by above-average trading volume. The recent changes in earnings estimates may not lead to additional price growth in the short run.

Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
Zacks Investment Research01 April 2024 Sentiment: POSITIVE

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Revvity's (RVTY) New Launch to Boost Research Productivity
Zacks Investment Research21 March 2024 Sentiment: POSITIVE

Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.

  • 1(current)
  • 2

What type of business is Revvity?

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

What sector is Revvity in?

Revvity is in the Healthcare sector

What industry is Revvity in?

Revvity is in the Diagnostics & Research industry

What country is Revvity from?

Revvity is headquartered in United States

When did Revvity go public?

Revvity initial public offering (IPO) was on 06 July 1965

What is Revvity website?

https://www.perkinelmer.com

Is Revvity in the S&P 500?

Yes, Revvity is included in the S&P 500 index

Is Revvity in the NASDAQ 100?

No, Revvity is not included in the NASDAQ 100 index

Is Revvity in the Dow Jones?

No, Revvity is not included in the Dow Jones index

When does Revvity report earnings?

The next expected earnings date for Revvity is 01 August 2024